HRP20171761T1 - Genetski modificirani miš s glavnim kompleksom histokompatibilnosti - Google Patents
Genetski modificirani miš s glavnim kompleksom histokompatibilnosti Download PDFInfo
- Publication number
- HRP20171761T1 HRP20171761T1 HRP20171761TT HRP20171761T HRP20171761T1 HR P20171761 T1 HRP20171761 T1 HR P20171761T1 HR P20171761T T HRP20171761T T HR P20171761TT HR P20171761 T HRP20171761 T HR P20171761T HR P20171761 T1 HRP20171761 T1 HR P20171761T1
- Authority
- HR
- Croatia
- Prior art keywords
- mouse
- polypeptide
- human
- rodent
- microglobulin
- Prior art date
Links
- 108700018351 Major Histocompatibility Complex Proteins 0.000 title claims 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 title claims 2
- 241000699670 Mus sp. Species 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 claims 46
- 108090000765 processed proteins & peptides Proteins 0.000 claims 46
- 102000004196 processed proteins & peptides Human genes 0.000 claims 46
- 241000283984 Rodentia Species 0.000 claims 30
- 239000002773 nucleotide Substances 0.000 claims 27
- 125000003729 nucleotide group Chemical group 0.000 claims 27
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims 19
- 102000015736 beta 2-Microglobulin Human genes 0.000 claims 17
- 101000937544 Homo sapiens Beta-2-microglobulin Proteins 0.000 claims 6
- 241001529936 Murinae Species 0.000 claims 6
- 101000937526 Mus musculus Beta-2-microglobulin Proteins 0.000 claims 5
- 108700043516 mouse H-2Kb Proteins 0.000 claims 5
- 230000001105 regulatory effect Effects 0.000 claims 5
- 102000025850 HLA-A2 Antigen Human genes 0.000 claims 4
- 108010074032 HLA-A2 Antigen Proteins 0.000 claims 4
- 230000001086 cytosolic effect Effects 0.000 claims 4
- 108700024394 Exon Proteins 0.000 claims 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 108010075704 HLA-A Antigens Proteins 0.000 claims 2
- 102000011786 HLA-A Antigens Human genes 0.000 claims 2
- 210000001161 mammalian embryo Anatomy 0.000 claims 2
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 claims 1
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 claims 1
- 108010058607 HLA-B Antigens Proteins 0.000 claims 1
- 108010052199 HLA-C Antigens Proteins 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Environmental Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Engineering & Computer Science (AREA)
- Animal Husbandry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (38)
1. Glodavac koji na lokusu endogenog glavnog sustava tkivne podudarnosti (MHC I) ima nukleotidni slijed kojim se kodira kimerni MHC I polipeptid čovjeka/glodavca,
pri čemu se ljudski dio kimernog polipeptida sastoji od domena ljudskog MHC I polipeptida α1, α2, i α3,
pri čemu se dio glodavca kimernog polipeptida sastoji od transmembranske i citoplazmatske domene endogenog polipeptida glodavca MHC I i
pri čemu glodavac izražava kimerni MHC I polipeptid čovjeka/glodavca.
2. U glodavca iz zahtjeva 1. glodavac ne izražava domene α1, α2, i α3 endogenog MHC I polipeptida iz endogenog MHC I lokusa glodavca.
3. Glodavac iz zahtjeva 1. ili zahtjeva 2. pri čemu je nukleotidni slijed operabilno povezan s endogenim regulatornim elementima glodavca.
4. Glodavac iz bilo kojeg od prethodnih zahtjeva, pri čemu se ljudski dio kimernog polipeptida sastoji od vodećeg ljudskog slijeda.
5. Glodavac iz bilo kojeg od prethodnih zahtjeva, pri čemu je ljudski MHC I polipeptid odabran iz grupe koja se sastoji od HLA-A, HLA-B i HLA-C.
6. Glodavac iz bilo kojeg od prethodnih zahtjeva, pri čemu je glodavac miš.
7. Miš iz zahtjeva 6. pri čemu je endogeni lokus mišji lokus H-2K.
8. Miš iz zahtjeva 7. pri čemu je endogeni MHC I polipeptid glodavca H-2K.
9. Miš iz zahtjeva 6. na endogenom lokusu H-2K sadrži nukleotidni slijed kojim se kodira kimerni ljudski/mišji MHC I polipeptid,
pri čemu se ljudski dio kimernog polipeptida sastoji od domena α1, α2 i α3 ljudskog polipeptida HLA-A2, a mišji se dio sastoji od transmembranske i citoplazmatske domene mišjeg H-2K polipeptida i
pri čemu miš izražava kimerni HLA-A2/H-2K polipeptid.
10. U miša iz zahtjeva 9. miš ne izražava domene α1, α2, i α3 mišjeg H-2K polipeptida iz endogenog H-2K lokusa.
11. Miš iz zahtjeva 9. ili 10. pri čemu se ljudski dio kimernog polipeptida sastoji od vodećeg ljudskog slijeda.
12. Miš iz bilo kojeg zahtjeva 9. – 11. pri čemu je nukleotidni slijed operabilno povezan s endogenim regulatornim elementima miša.
13. Miš iz bilo kojeg zahtjeva 9. – 12. pri čemu je HLA-A2 polipeptid HLA-A2.1 polipeptid.
14. Miš iz bilo kojeg zahtjeva 9. – 13. pri čemu je mišji H-2K lokus H-2Kb lokus.
15. Metoda kojom se izmjenjuje mišji MHC I lokus kako bi se izrazio kimerni ljudski/mišji MHC I polipeptid, pri čemu se metoda sastoji od zamjene nukleotidnog slijeda kojim se kodiraju domene α1, α2 i α3 na endogenom MHC I lokusu mišjeg MHC I polipeptida nukleotidnim slijedom kojim se kodiraju domene α1, α2 i α3 ljudskog MHC I polipeptida, pri čemu miš izražava transmembranske i citoplazmatske domene mišjeg MHC I polipeptida.
16. Metoda iz zahtjeva 15., pri čemu miš ne izražava domene α1, α2, i α3 mišjeg MHC I polipeptida iz endogenog mišjeg MHC I lokusa.
17. Metoda iz zahtjeva 15. ili zahtjeva 16. pri čemu je mišji MHC I lokus H-2K lokus, a mišji MHC I polipeptid H-2K polipeptid.
18. Metoda iz bilo kojeg zahtjeva 15. – 17. pri čemu je ljudski MHC I polipeptid HLA-A polipeptid.
19. Metoda iz bilo kojeg zahtjeva 15. – 18. gdje se zamjena vrši na jednoj ES stanici, a ta se jedna ES stanica uvodi u mišji embrij kako bi nastao miš.
20. Glodavac koji prema bilo kojem od zahtjeva 1. – 14. nadalje na endogenom lokusu β2 mikroglobulina glodavca sadrži nukleotidni slijed kojim se kodira polipeptid koji sadrži ljudski slijed aminokiselina β2 mikroglobulina, pri čemu glodavac izražava ljudski ili humanizirani polipeptid β2 mikroglobulina.
21. U glodavca iz zahtjeva 20. glodavac ne izražava funkcionalni endogeni polipeptid β2 mikroglobulina iz endogenog lokusa β2 mikroglobulina glodavca.
22. Glodavac iz zahtjeva 20. ili zahtjeva 21. pri čemu je nukleotidni slijed operabilno povezan s endogenim regulatornim elementima β2 mikroglobulina glodavca.
23. Glodavac iz bilo kojeg od zahtjeva 20. – 22. pri čemu nukleotidni slijed sadrži nukleotidni slijed koji je izložen od eksona 2. do eksona 4. ljudskog gena β2 mikroglobulina.
24. Glodavac iz bilo kojeg od zahtjeva 20. – 23. pri čemu nukleotidni slijed sadrži nukleotidne sljedove koji su izloženi u eksonima 2., 3. i 4. ljudskog gena β2 mikroglobulina.
25. Glodavac iz bilo kojeg od zahtjeva 20. – 24. pri čemu nukleotidni slijed nadalje sadrži nukleotidni slijed koji je izložen u eksonu 1. gena β2 mikroglobulina glodavca.
26. Glodavac iz bilo kojeg od zahtjeva 20. – 25., pri čemu je glodavac miš.
27. Metoda prema bilo kojem od zahtjeva 15. – 19., pri čemu metoda dodatno sadrži izmjenu mišjeg lokusa β2 mikroglobulina kako bi izražavao ljudski ili humanizirani polipeptid β2 mikroglobulina tako da se na endogenom mišjem lokusu β2 mikroglobulina nukleotidni slijed kojim se kodira mišji polipeptid β2 mikroglobulina zamijeni nukleotidnim slijedom kojim se kodira ljudski ili humanizirani polipeptid β2 mikroglobulina.
28. Metoda iz zahtjeva 27. pri čemu miš ne izražava funkcionalni mišji polipeptid β2 mikroglobulina iz endogenog lokusa β2 mikroglobulina.
29. Metoda iz zahtjeva 27. ili 28. pri čemu nukleotidni slijed kojim se kodira ljudski ili humanizirani polipeptid β2 mikroglobulina sadrži nukleotidni slijed koji je izložen od eksona 2. do eksona 4. ljudskog gena β2 mikroglobulina.
30. Metoda iz bilo kojeg zahtjeva 27. – 29. pri čemu nukleotidni slijed kojim se kodira ljudski ili humanizirani polipeptid β2 mikroglobulina sadrži nukleotidne sljedove koji su izloženi u eksonima 2., 3. i 4. ljudskog gena β2 mikroglobulina.
31. Metoda iz bilo kojeg od zahtjeva 27. – 30. pri čemu izmijenjeni lokus zadržava nukleotidni slijed eksona 1. mišjeg gena β2 mikroglobulina.
32. Metoda iz bilo kojeg zahtjeva 27. – 31. gdje se zamjena vrši na jednoj ES stanici, a ta se jedna ES stanica uvodi u mišji embrij kako bi nastao miš.
33. Genom miša iz zahtjeva 9. sastoji se od:
prvog nukleotidnog slijeda kojim se kodira kimerni ljudski/mišji MHC I polipeptid, pri čemu se ljudski dio kimernog polipeptida sastoji od domena α1, α2 i α3 ljudskog HLA-A2, a mišji se dio sastoji od transmembranske i citoplazmatske domene mišjeg H-2K, i
drugog nukleotidnog slijeda kojim se kodira ljudski ili humanizirani polipeptid β2 mikroglobulina,
pri čemu se prvi nukleotidni slijed nalazi na endogenom H-2K lokus, a drugi se nukleotidni slijed nalazi na endogenom mišjem lokusu β2 mikroglobulina te
pri čemu miš izražava kimerni ljudski/mišji MHC I polipeptid i ljudski ili humanizirani polipeptid β2 mikroglobulina.
34. Miš iz zahtjeva 33. pri čemu miš ne izražava endogene mišje polipeptide H-2K i β2 mikroglobulina iz njihovih endogenih lokusa.
35. Miš iz zahtjeva 33. i 34., pri čemu je prvi nukleotidni slijed operabilno povezan s endogenim mišjim H-2K regulatornim elementima, a drugi je nukleotidni slijed operabilno povezan s endogenim mišjim regulatornim elementima β2 mikroglobulina.
36. Miš iz bilo kojeg od zahtjeva 33. – 35. pri čemu drugi nukleotidni slijed sadrži nukleotidni slijed koji je izložen od eksona 2. do eksona 4. ljudskog gena β2 mikroglobulina.
37. Miš iz bilo kojeg od zahtjeva 33. – 36. pri čemu drugi nukleotidni slijed sadrži nukleotidne sljedove koji su izloženi u eksonima 2., 3. i 4. ljudskog gena β2 mikroglobulina.
38. Miš iz bilo kojeg od zahtjeva 33. – 37. pri čemu se u izražavanju ljudskog ili humaniziranog polipeptida β2 mikroglobulina povećava izražavanje kimernog ljudskog/mišjeg MHC I polipeptida u usporedbi s izražavanjem kimernog ljudskog/mišjeg MHC I polipeptida gdje ne dolazi do izražavanja ljudskog ili humaniziranog polipeptida β2 mikroglobulina.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161552587P | 2011-10-28 | 2011-10-28 | |
| US201161552582P | 2011-10-28 | 2011-10-28 | |
| US201261700908P | 2012-09-14 | 2012-09-14 | |
| EP12787255.4A EP2770821B1 (en) | 2011-10-28 | 2012-10-26 | Genetically modified major histocompatibility complex mice |
| PCT/US2012/062042 WO2013063346A1 (en) | 2011-10-28 | 2012-10-26 | Genetically modified major histocompatibility complex mice |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20171761T1 true HRP20171761T1 (hr) | 2017-12-29 |
Family
ID=47178940
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171761TT HRP20171761T1 (hr) | 2011-10-28 | 2017-11-15 | Genetski modificirani miš s glavnim kompleksom histokompatibilnosti |
| HRP20191420 HRP20191420T1 (hr) | 2011-10-28 | 2019-08-06 | Miševi koji su genetski modificirani s glavnim histokompatibilnim kompleksom |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191420 HRP20191420T1 (hr) | 2011-10-28 | 2019-08-06 | Miševi koji su genetski modificirani s glavnim histokompatibilnim kompleksom |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US9615550B2 (hr) |
| EP (4) | EP3563680B1 (hr) |
| JP (4) | JP6154391B2 (hr) |
| KR (3) | KR101921126B1 (hr) |
| CN (3) | CN104039132B9 (hr) |
| AU (3) | AU2012324016C1 (hr) |
| BR (1) | BR112014009259A2 (hr) |
| CA (2) | CA2850387A1 (hr) |
| CY (2) | CY1119657T1 (hr) |
| DK (2) | DK3262932T3 (hr) |
| ES (3) | ES2741649T3 (hr) |
| HK (2) | HK1200272A1 (hr) |
| HR (2) | HRP20171761T1 (hr) |
| HU (2) | HUE035652T2 (hr) |
| IL (3) | IL232097A (hr) |
| LT (2) | LT2770821T (hr) |
| MX (2) | MX355725B (hr) |
| MY (2) | MY178723A (hr) |
| NZ (1) | NZ734532A (hr) |
| PL (2) | PL2770821T3 (hr) |
| PT (2) | PT3262932T (hr) |
| RS (2) | RS56656B1 (hr) |
| SG (2) | SG10201603188SA (hr) |
| SI (2) | SI2770821T1 (hr) |
| WO (1) | WO2013063346A1 (hr) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102084927B1 (ko) | 2011-10-28 | 2020-03-06 | 리제너론 파아마슈티컬스, 인크. | 사람화된 ｉｌ-6 및 ｉｌ-6 수용체 |
| US9591835B2 (en) | 2011-10-28 | 2017-03-14 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex animals |
| CN111484999A (zh) * | 2013-02-20 | 2020-08-04 | 瑞泽恩制药公司 | 人源化的t细胞共受体的小鼠 |
| US20150342163A1 (en) | 2013-02-22 | 2015-12-03 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
| CA2900824A1 (en) * | 2013-02-22 | 2014-08-28 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized major histocompatibility complex |
| WO2014164640A1 (en) * | 2013-03-11 | 2014-10-09 | Regeneron Pharmaceuticals, Inc. | Transgenic mice expressing chimeric major histocompatibility complex (mhc) class i molecules |
| IL297607B2 (en) | 2013-09-23 | 2024-01-01 | Regeneron Pharma | Non-human animals with a humanized gene for SIGNAL-REGULATORY PROTEIN |
| PT3138397T (pt) | 2013-10-15 | 2019-03-26 | Regeneron Pharma | Animais il-15 humanizados |
| JP6236461B2 (ja) * | 2013-10-18 | 2017-11-22 | 大鵬薬品工業株式会社 | Ｈｌａクラスｉ発現非ヒト動物 |
| WO2015157415A1 (en) | 2014-04-08 | 2015-10-15 | Regeneron Pharmaceuticals, Inc. | Non-human animals having humanized fc-gamma receptors |
| MX2016014504A (es) | 2014-05-05 | 2017-05-23 | Regeneron Pharma | Animales c5 y c3 humanizados. |
| NO2785538T3 (hr) | 2014-05-07 | 2018-08-04 | ||
| WO2015196051A1 (en) | 2014-06-19 | 2015-12-23 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized programmed cell death 1 gene |
| RU2017113134A (ru) | 2014-09-19 | 2018-10-19 | Регенерон Фармасьютикалз, Инк. | Химерные антигенные рецепторы |
| RS63410B1 (sr) | 2014-11-24 | 2022-08-31 | Regeneron Pharma | Ne-humane životinje koje eksprimiraju humanizovani cd3 kompleks |
| NZ731471A (en) | 2014-12-05 | 2021-12-24 | Regeneron Pharma | Non-human animals having a humanized cluster of differentiation 47 gene |
| IL282649B (en) * | 2014-12-09 | 2022-07-01 | Regeneron Pharma | Non-human animals with a humanized gene for differentiation cluster 274 |
| CA2969847A1 (en) * | 2014-12-10 | 2016-06-16 | Regents Of The University Of Minnesota | Genetically modified cells, tissues, and organs for treating disease |
| HRP20231039T1 (hr) | 2015-04-06 | 2023-12-22 | Regeneron Pharmaceuticals, Inc. | Imunosni odgovori posredovani humaniziranim t stanicama kod ne-humanih životinja |
| EP4248740A3 (en) * | 2015-04-13 | 2023-12-27 | Regeneron Pharmaceuticals, Inc. | Humanized sirpa-il15 knockin mice and methods of use thereof |
| WO2017087780A1 (en) | 2015-11-20 | 2017-05-26 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized lymphocyte-activation gene 3 |
| ES2886958T3 (es) | 2016-02-29 | 2021-12-21 | Regeneron Pharma | Roedores que tienen un gen TMPRSS humanizado |
| CN116458475A (zh) | 2016-06-03 | 2023-07-21 | 瑞泽恩制药公司 | 表达外源末端脱氧核苷酸转移酶的非人动物 |
| CN109456942A (zh) * | 2017-09-06 | 2019-03-12 | 亘喜生物科技（上海）有限公司 | 通用型嵌合抗原受体t细胞制备技术 |
| RU2020112751A (ru) * | 2017-09-29 | 2021-10-29 | Регенерон Фармасьютикалз, Инк. | Отличные от человека животные, у которых экспрессируется гуманизированный комплекс c1q |
| CA3076377A1 (en) | 2017-11-30 | 2019-06-06 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized trkb locus |
| MX2020009989A (es) * | 2018-03-24 | 2020-10-14 | Regeneron Pharma | Animales no humanos geneticamente modificados para generar anticuerpos terapeuticos contra complejos peptidos-mhc, metodos de elaboracion y usos de estos. |
| EP3772926A1 (en) | 2018-03-26 | 2021-02-17 | Regeneron Pharmaceuticals, Inc. | Humanized rodents for testing therapeutic agents |
| SG11202011284RA (en) | 2018-07-16 | 2020-12-30 | Regeneron Pharma | Non-human animal models of ditra disease and uses thereof |
| WO2020206139A1 (en) | 2019-04-04 | 2020-10-08 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized coagulation factor 12 locus |
| KR20220016869A (ko) | 2019-06-04 | 2022-02-10 | 리제너론 파마슈티칼스 인코포레이티드 | 베타-슬립 돌연변이를 갖는 인간화 ttr 좌위를 포함하는 비-인간 동물 및 사용 방법 |
| KR20220017939A (ko) | 2019-06-07 | 2022-02-14 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화 알부민 좌위를 포함하는 비-인간 동물 |
| CN113105555B (zh) * | 2020-01-10 | 2023-05-30 | 百奥赛图(北京)医药科技股份有限公司 | Mhc分子人源化的非人动物的构建方法及应用 |
| WO2022133155A1 (en) * | 2020-12-16 | 2022-06-23 | Xenotherapeutics, Inc. | Humanization of beta2-microglobulin in porcine genome resulting in functional expression of human βeta2-microglobulin within donor cells, tissues, or organs |
| KR20230147048A (ko) | 2020-12-16 | 2023-10-20 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화 Fc 알파 수용체를 발현하는 마우스 |
| BR112023018874A2 (pt) | 2021-03-31 | 2023-10-03 | Regeneron Pharma | Camundongos geneticamente modificados compreendendo componentes do sistema imunológico celular humanizado com diversidade melhorada do repertório de tcrb |
| WO2023240124A1 (en) | 2022-06-07 | 2023-12-14 | Regeneron Pharmaceuticals, Inc. | Pseudotyped viral particles for targeting tcr-expressing cells |
| WO2023240109A1 (en) | 2022-06-07 | 2023-12-14 | Regeneron Pharmaceuticals, Inc. | Multispecific molecules for modulating t-cell activity, and uses thereof |
| US20240099279A1 (en) | 2022-09-22 | 2024-03-28 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice expressing components of human cellular immune system |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0950707B1 (en) | 1989-07-25 | 2009-02-18 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| US5574205A (en) | 1989-07-25 | 1996-11-12 | Cell Genesys | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| GB9100481D0 (en) | 1991-01-10 | 1991-02-20 | Inst Nat Sante Rech Med | Genetically engineered mice |
| AU2661692A (en) | 1991-09-19 | 1993-04-27 | President And Fellows Of Harvard College | Transgenic mhc class i and class ii antigen-deficient mammals |
| EP0663952A4 (en) | 1992-09-11 | 1997-06-11 | Univ California | TRANSGENIC NON-HUMAN ANIMALS WITH TARGETED INTERRUPTED TRANSDUCTION GENES IN LYMPHOCYTES. |
| US5523226A (en) | 1993-05-14 | 1996-06-04 | Biotechnology Research And Development Corp. | Transgenic swine compositions and methods |
| GB9315303D0 (en) | 1993-07-23 | 1993-09-08 | Zeneca Ltd | Polypeptide |
| US5965787A (en) | 1995-08-31 | 1999-10-12 | Mayo Foundation For Medical Education And Research | HLA-DRBI peptides with specific binding affinity for HLA-DQ molecules: prevention and treatment of rheumatoid arthritis |
| US6002066A (en) | 1996-01-16 | 1999-12-14 | Ortho Pharmaceutical Corp. | H2-M modified transgenic mice |
| CA2246333A1 (en) | 1996-03-05 | 1997-09-12 | The Scripps Research Institute | Recombinant constructs encoding t cell receptors specific for human hla-restricted tumor antigens |
| KR100942002B1 (ko) | 1996-12-03 | 2010-02-12 | 암젠 프레몬트 인코포레이티드 | 복수의 ｖｈ 및 ｖｋ 부위를 함유하는 사람 면역글로불린 유전자좌를 갖는 형질전환된 포유류 및 이로부터 생성된 항체 |
| ATE423789T1 (de) | 1997-09-16 | 2009-03-15 | Univ Oregon Health & Science | Rekombinante mhc-moleküle welche nützlich sind für die manipulation von antigen-spezifischen t- zellen |
| US6372955B1 (en) | 1998-02-17 | 2002-04-16 | Ortho Mcneil Pharmaceutical, Inc. | Methods for Producing B cells and antibodies from H2-O modified transgenic mice |
| WO2001027291A1 (en) * | 1999-10-12 | 2001-04-19 | Institut Pasteur | Design of a polyepitopic construct for the induction of hla-a2.1 restricted hiv 1 specific ctl responses using hhd mice |
| US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20050050580A1 (en) * | 2000-12-13 | 2005-03-03 | Masashi Gotoh | Transgenic animal expressing hla-a24 and utilization thereof |
| JP2005505236A (ja) * | 2000-12-19 | 2005-02-24 | アルトー バイオサイエンス コーポレイション | ヒト化免疫系を含むトランスジェニック動物 |
| FR2827302B1 (fr) * | 2001-07-13 | 2003-10-10 | Genoway | Cellule et animal transgenique modelisant la presentation antigenique humaine et leurs utilisations |
| US8895020B2 (en) | 2002-04-19 | 2014-11-25 | Washington University | Single chain trimers and uses therefor |
| US7179645B2 (en) * | 2002-09-24 | 2007-02-20 | Antigen Express, Inc. | Ii-Key/antigenic epitope hybrid peptide vaccines |
| US7663017B2 (en) * | 2003-07-30 | 2010-02-16 | Institut Pasteur | Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications |
| JP4857450B2 (ja) | 2004-03-09 | 2012-01-18 | 財団法人名古屋産業科学研究所 | ヒト関節リウマチの病態を再現するトランスジェニック非ヒト哺乳動物 |
| CA2583750C (en) | 2004-10-19 | 2015-11-24 | Regeneron Pharmaceuticals, Inc. | Methods for generating a rodent having a genetic modification |
| JP4830139B2 (ja) * | 2006-03-10 | 2011-12-07 | 学校法人明治大学 | クローン胚の作製方法 |
| NZ547859A (en) * | 2006-06-09 | 2009-05-31 | Dec Int Nz Ltd | Treatment method and composition for mastitis |
| EP1878798A1 (en) | 2006-07-13 | 2008-01-16 | Institut Pasteur | Method of producing a multichimeric mouse and applications to study the immunopathogenesis of human tissue-specific pathologies |
| EP1878342A1 (en) | 2006-07-13 | 2008-01-16 | Institut Pasteur | Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses |
| WO2008133857A1 (en) * | 2007-04-23 | 2008-11-06 | Schering Corporation | Anti-mdl-1 antibodies |
| TWI476280B (zh) | 2008-03-07 | 2015-03-11 | Regeneron Pharma | 來自二倍體宿主胚胎注射之ｅｓ－細胞衍生的老鼠 |
| US20090328240A1 (en) | 2008-06-24 | 2009-12-31 | Sing George L | Genetically modified mice as predictors of immune response |
| EP2153845A1 (en) * | 2008-08-13 | 2010-02-17 | Julius-Maximilians-Universität Würzburg | Endoglin peptides, vaccines and methods for preparing the same |
| DK3241435T3 (da) * | 2009-07-08 | 2021-08-23 | Kymab Ltd | Dyremodeller og terapeutiske molekyler |
| WO2012039779A1 (en) | 2010-09-24 | 2012-03-29 | The United States Of America As Represented By The Secretary Of The Navy | Humanized transgenic mouse model |
| CN111484999A (zh) | 2013-02-20 | 2020-08-04 | 瑞泽恩制药公司 | 人源化的t细胞共受体的小鼠 |
| CA2900824A1 (en) | 2013-02-22 | 2014-08-28 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized major histocompatibility complex |
| US20150342163A1 (en) | 2013-02-22 | 2015-12-03 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
| CN105683383B (zh) * | 2013-06-03 | 2020-08-21 | 赛拉福柯蒂斯公司 | 含有I型MHC、II型MHC或β2微球蛋白上游启动子序列的慢病毒载体 |
| JP6236461B2 (ja) * | 2013-10-18 | 2017-11-22 | 大鵬薬品工業株式会社 | Ｈｌａクラスｉ発現非ヒト動物 |
| HRP20231039T1 (hr) | 2015-04-06 | 2023-12-22 | Regeneron Pharmaceuticals, Inc. | Imunosni odgovori posredovani humaniziranim t stanicama kod ne-humanih životinja |
-
2012
- 2012-10-26 HU HUE12787255A patent/HUE035652T2/en unknown
- 2012-10-26 SG SG10201603188SA patent/SG10201603188SA/en unknown
- 2012-10-26 MX MX2014004895A patent/MX355725B/es active IP Right Grant
- 2012-10-26 AU AU2012324016A patent/AU2012324016C1/en active Active
- 2012-10-26 LT LTEP12787255.4T patent/LT2770821T/lt unknown
- 2012-10-26 MY MYPI2017703836A patent/MY178723A/en unknown
- 2012-10-26 EP EP19167619.6A patent/EP3563680B1/en active Active
- 2012-10-26 ES ES17184955T patent/ES2741649T3/es active Active
- 2012-10-26 CA CA2850387A patent/CA2850387A1/en active Pending
- 2012-10-26 EP EP12787255.4A patent/EP2770821B1/en active Active
- 2012-10-26 MX MX2020010763A patent/MX2020010763A/es unknown
- 2012-10-26 KR KR1020147014476A patent/KR101921126B1/ko active IP Right Grant
- 2012-10-26 RS RS20171195A patent/RS56656B1/sr unknown
- 2012-10-26 KR KR1020207002887A patent/KR102295746B1/ko active IP Right Grant
- 2012-10-26 PL PL12787255T patent/PL2770821T3/pl unknown
- 2012-10-26 WO PCT/US2012/062042 patent/WO2013063346A1/en active Application Filing
- 2012-10-26 PT PT17184955T patent/PT3262932T/pt unknown
- 2012-10-26 ES ES12787255.4T patent/ES2651517T3/es active Active
- 2012-10-26 EP EP17184955.7A patent/EP3262932B1/en active Active
- 2012-10-26 CN CN201280060540.8A patent/CN104039132B9/zh active Active
- 2012-10-26 CN CN202110831383.7A patent/CN113564188A/zh active Pending
- 2012-10-26 NZ NZ734532A patent/NZ734532A/en unknown
- 2012-10-26 RS RS20190998A patent/RS59082B1/sr unknown
- 2012-10-26 PT PT127872554T patent/PT2770821T/pt unknown
- 2012-10-26 CN CN201710347715.8A patent/CN107254480B/zh active Active
- 2012-10-26 SI SI201231136T patent/SI2770821T1/en unknown
- 2012-10-26 BR BR112014009259-1A patent/BR112014009259A2/pt not_active Application Discontinuation
- 2012-10-26 CA CA3074400A patent/CA3074400A1/en active Pending
- 2012-10-26 KR KR1020187033187A patent/KR102074145B1/ko active IP Right Grant
- 2012-10-26 EP EP23193595.8A patent/EP4311833A3/en active Pending
- 2012-10-26 ES ES19167619T patent/ES2962287T3/es active Active
- 2012-10-26 PL PL17184955T patent/PL3262932T3/pl unknown
- 2012-10-26 DK DK17184955.7T patent/DK3262932T3/da active
- 2012-10-26 HU HUE17184955A patent/HUE045879T2/hu unknown
- 2012-10-26 DK DK12787255.4T patent/DK2770821T3/da active
- 2012-10-26 SG SG11201400933VA patent/SG11201400933VA/en unknown
- 2012-10-26 LT LTEP17184955.7T patent/LT3262932T/lt unknown
- 2012-10-26 JP JP2014539029A patent/JP6154391B2/ja active Active
- 2012-10-26 MY MYPI2014000784A patent/MY164836A/en unknown
- 2012-10-26 US US13/661,159 patent/US9615550B2/en active Active
- 2012-10-26 SI SI201231650T patent/SI3262932T1/sl unknown
-
2014
- 2014-04-13 IL IL232097A patent/IL232097A/en active IP Right Grant
-
2015
- 2015-01-29 HK HK15101011.6A patent/HK1200272A1/xx unknown
-
2016
- 2016-04-27 AU AU2016202688A patent/AU2016202688B2/en active Active
-
2017
- 2017-02-22 US US15/439,828 patent/US10869466B2/en active Active
- 2017-04-30 IL IL252022A patent/IL252022A0/en active IP Right Grant
- 2017-06-01 JP JP2017109327A patent/JP6574457B2/ja active Active
- 2017-11-15 HR HRP20171761TT patent/HRP20171761T1/hr unknown
- 2017-11-22 CY CY20171101223T patent/CY1119657T1/el unknown
- 2017-12-22 AU AU2017279797A patent/AU2017279797C1/en active Active
-
2018
- 2018-06-29 HK HK18108466.8A patent/HK1249712B/zh unknown
- 2018-08-20 IL IL26123918A patent/IL261239B/en active IP Right Grant
-
2019
- 2019-02-06 JP JP2019019707A patent/JP6866409B2/ja active Active
- 2019-08-06 HR HRP20191420 patent/HRP20191420T1/hr unknown
- 2019-08-07 CY CY20191100840T patent/CY1121869T1/el unknown
-
2020
- 2020-05-07 JP JP2020081774A patent/JP2020146041A/ja not_active Withdrawn
- 2020-08-12 US US16/991,283 patent/US20200375160A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171761T1 (hr) | Genetski modificirani miš s glavnim kompleksom histokompatibilnosti | |
| HRP20200305T1 (hr) | Genetski modificirani miševi koji eksprimiraju kimerne molekule glavnog histokompatibilnog kompleksa (mhc) ii | |
| JP2014532412A5 (hr) | ||
| dos Reis et al. | Phylogenomic datasets provide both precision and accuracy in estimating the timescale of placental mammal phylogeny | |
| Koshikawa et al. | Gain of cis-regulatory activities underlies novel domains of wingless gene expression in Drosophila | |
| Parham et al. | Variable NK cell receptors exemplified by human KIR3DL1/S1 | |
| Matsuda et al. | DMY gene induces male development in genetically female (XX) medaka fish | |
| Hansen et al. | Discovery of a unique Ig heavy-chain isotype (IgT) in rainbow trout: Implications for a distinctive B cell developmental pathway in teleost fish | |
| Flajnik et al. | Evolution of the B7 family: co-evolution of B7H6 and NKp30, identification of a new B7 family member, B7H7, and of B7's historical relationship with the MHC | |
| HRP20192311T1 (hr) | Adam6 miševi | |
| Eckalbar et al. | Somitogenesis in the anole lizard and alligator reveals evolutionary convergence and divergence in the amniote segmentation clock | |
| FI3280257T3 (fi) | Humanisoituja t-soluvälitteisiä immuunivasteita ei-ihmiseläimillä | |
| JP2019521668A5 (hr) | ||
| JP2015523863A5 (hr) | ||
| Rajalingam | Diversity of killer cell immunoglobulin-like receptors and disease | |
| Domené et al. | Enhancer turnover and conserved regulatory function in vertebrate evolution | |
| Driller et al. | Stop and Go–Waves of tarsier dispersal mirror the genesis of Sulawesi island | |
| Cal et al. | Loss‐of‐function mutations in the melanocortin 1 receptor cause disruption of dorso‐ventral countershading in teleost fish | |
| Liu et al. | Characterization of the CD3ζ, CD3γδ and CD3ε subunits of the T cell receptor complex in Atlantic salmon | |
| Carducci et al. | An intriguing relationship between teleost Rex3 retroelement and environmental temperature | |
| Guselnikov et al. | Fugu rubripes possesses genes for the entire set of the ITAM-bearing transmembrane signal subunits | |
| Q Irvine | Study of Cis-regulatory Elements in the Ascidian Ciona intestinalis | |
| Lalueza-Fox | Agreements and misunderstandings among three scientific fields: paleogenomics, archaeology, and human paleontology | |
| Gerritsen et al. | Characterization of the ferret TRB locus guided by V, D, J, and C gene expression analysis | |
| Breaux et al. | The Florida manatee (Trichechus manatus latirostris) immunoglobulin heavy chain suggests the importance of clan III variable segments in repertoire diversity |